Slingshot Insights | Ipxl Overview

IPXL Overview

Upcoming Projects (IPXL)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (IPXL)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (IPXL)

FDA has approved the Company's supplemental new drug application sNDA for EMVERM (mebendazole) 100 mg chewable tablets; commercial distribution of EMVERM expected in the early second quarter of 2016
Ticker: IPXL
Occurred on: Apr 13, 2016
Impax Receives Tentative FDA Approval for Generic Version of Vytorin (ezetimibe and simvastatin) Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg
Ticker: IPXL
Occurred on: Feb 02, 2016

Strategic Initiatives (IPXL)

Impax Signs Definitive Agreements to Acquire Generic Products
Tickers: IPXL, TEVA
Announcement Date: Jun 21, 2016